13.75
Atrium Therapeutics Inc Azioni (RNA) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
| Data di fine periodo | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
| Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
| Revenues |
93.11%
0.86
|
12.47 | 3.847 | 1.573 | 2.336 |
|
|
26.86%
255.34
|
201.28 | 174.99 | 133.09 | 100.47 |
| Benefits Costs and Expenses |
237.96
|
- | - | 117.35 | - |
| Costs And Expenses |
18.22%
237.96
|
201.28 | 174.99 | 117.35 | 100.47 |
| Operating Income/Loss |
34.78%
-254.48
|
-188.81 | -171.14 | -131.52 | -98.13 |
| Nonoperating Income/Loss |
20.98%
17.38
|
14.36 | 13.83 | 15.74 | 17.74 |
| Income/Loss From Continuing Operations Before Tax |
2,001%
-237.10
|
12.47 | -157.31 | -115.77 | 2.336 |
| Income/Loss From Continuing Operations After Tax |
35.92%
-237.10
|
-174.44 | -157.31 | -115.77 | -80.40 |
|
|
35.92%
-237.10
|
-174.44 | -157.31 | -115.77 | -80.40 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
96.06%
5.429
|
137.90 | 129.62 | 129.23 | 123.38 |
| Diluted Average Shares |
96.06%
5.429
|
137.90 | 129.62 | 129.23 | 123.38 |
| Basic Earnings Per Share |
25.20%
-1.59
|
-1.27 | -1.21 | -0.90 | -0.65 |
| Diluted Earnings Per Share |
25.20%
-1.59
|
-1.27 | -1.21 | -0.90 | -0.65 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):